Raymond James Financial Inc. Invests $36.18 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Raymond James Financial Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 404,461 shares of the medical equipment provider's stock, valued at approximately $36,183,000. Raymond James Financial Inc. owned 0.58% of Lantheus as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Swedbank AB lifted its holdings in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares during the period. Keybank National Association OH bought a new stake in shares of Lantheus during the 4th quarter worth about $27,526,000. Norges Bank acquired a new stake in shares of Lantheus in the 4th quarter worth approximately $26,189,000. Wellington Management Group LLP bought a new position in shares of Lantheus in the fourth quarter valued at approximately $20,022,000. Finally, Amundi increased its stake in shares of Lantheus by 529.5% during the fourth quarter. Amundi now owns 176,952 shares of the medical equipment provider's stock valued at $16,633,000 after acquiring an additional 148,842 shares during the period. Institutional investors own 99.06% of the company's stock.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Trading Down 1.0 %

Shares of NASDAQ LNTH traded down $1.05 during mid-day trading on Tuesday, reaching $99.57. The company had a trading volume of 813,226 shares, compared to its average volume of 953,863. Lantheus Holdings, Inc. has a 1-year low of $62.59 and a 1-year high of $126.89. The stock has a market cap of $6.82 billion, a PE ratio of 16.57 and a beta of 0.20. The company has a 50-day moving average price of $96.11 and a two-hundred day moving average price of $95.36.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock worth $6,016,046 over the last 90 days. 2.00% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.